INNOSTAR ORD A (SHH) EQSW Exp:

688710 · SHG · Healthcare / Drug Manufacturers - General

87.09CNY-6.84 (-7.28%)

Price History

Full chart

Market Stats

Previous Close93.93

Open93.89

Day Range86.91 – 93.89

52-Week Range40.26 – 107.99

Volume2.45M

Market Cap14.83B

P/E (TTM)618.82

Forward P/E0.00

EPS0.17

Dividend Yield0.00%

Beta-0.35

50-Day Avg87.27

200-Day Avg67.56

About

Shanghai InnoStar Bio-tech Co., Ltd. provides drug research and development services in China and internationally. It offers screening, nonclinical assessment stage, and clinical development stage services in the areas of chemical products, biologics, cell and gene therapeutics, radiopharmaceuticals, and traditional Chinese medicines. The company was founded in 2010 and is based in Shanghai, China.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - General
CEOMs. Yan Chang Ph.D.
Employees1.20K
HeadquartersNo. 199, Guoshoujing Road, Shanghai, China, 201203, China
Websitehttps://www.innostar.cn

Leadership

Ms. Yan Chang Ph.D.CEO, President & Director · b. 1974
Ms. Xiaohong GaoVP & CFO · b. 1982
Mr. Hua LiSenior Vice President · b. 1978
Ms. Yan LiSecretary to the Board · b. 1976
Fangjue YaoAccounting Supervisor
Dr. Sean Xiaochun Chen Ph.D.CSO

Financials

Income Statement

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	581.77M	863.07M	1.04B	1.14B	811.33M
Growth (%)	-	+48.35%	+20.32%	+9.94%	-28.94%
Cost of Revenue	358.49M	515.71M	585.49M	757.88M	600.73M
Gross Profit	223.28M	347.36M	452.94M	383.79M	210.59M
Gross Margin	38.38%	40.25%	43.62%	33.62%	25.96%
Operating Expense	114.29M	185.57M	219.33M	190.69M	187.72M
Operating Income	108.99M	161.79M	233.61M	193.10M	22.87M
Operating Margin	18.73%	18.75%	22.50%	16.91%	2.82%
EBITDA	-	224.96M	297.86M	249.99M	81.70M
EBITDA Margin	-	26.07%	28.68%	21.90%	10.07%
Net Income	86.73M	135.41M	194.45M	147.78M	-30.52M
Net Income Margin	14.91%	15.69%	18.72%	12.94%	-3.76%
R&D	27.87M	52.34M	60.43M	60.53M	45.78M
R&D as % of Total Revenue	4.79%	6.06%	5.82%	5.30%	5.64%
Interest Expense	10.99M	13.42M	12.01M	11.67M	8.54M
Interest Expense % of Total Revenue	1.89%	1.55%	1.16%	1.02%	1.05%

Balance Sheet

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	1.80B	2.62B	2.78B	3.22B	3.25B
Total Liabilities	1.05B	1.18B	1.14B	817.42M	891.41M
Total Equity	696.99M	1.41B	1.62B	2.39B	2.32B
Cash	638.77M	1.25B	1.16B	1.37B	1.29B

Cash Flow

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	143.53M	278.66M	168.19M	-96.60M	101.37M
Capital Expenditure	99.20M	145.99M	234.04M	287.55M	133.94M
Free Cash Flow	44.33M	132.67M	-65.85M	-384.15M	-32.57M
Dividends Paid	12.15M	32.27M	16.00K	228.00K	45.12M
FCF to OCF	30.88%	47.61%	-39.15%	397.67%	-32.13%
Dividend Paid to FCF	27.41%	24.32%	-0.02%	-0.06%	-138.52%

Key Statistics & Ratios

Market Cap14.83B

Enterprise Value13.41B

Trailing P/E618.82

Forward P/E0.00

Price / Sales16.46

Price / Book6.24

EPS0.17

Book Value16.79

Revenue (TTM)901.08M

Gross Profit (TTM)194.86M

EBITDA82.83M

Profit Margin2.65%

Operating Margin5.35%

Return on Equity1.07%

Return on Assets0.29%

Shares Outstanding140.98M

Shares Float118.89M

Beta-0.35

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio188.24%

Dividends

20251×

0.32Jul 23, 2025